NEDGROUP-INVESTMENTS
10.5.2023 09:50:27 CEST | Business Wire | Press release
Nedgroup Investments, a global asset manager with over $20bn AUM, is launching an in-house multi-boutique platform which will feature a growing range of active investment strategies characterised by deep alignment of client and fund manager interests.
Tom Caddick, Managing Director of Nedgroup Investments (International) commented: “It's harder for boutiques to set up now because of the onerous regulatory requirements and the difficulty of raising sufficient capital. We want to facilitate start-up boutiques to better serve the needs of our clients and provide a wider range of investment opportunity. We can create a more diverse fund management sector for the benefit of the end investor. I’m thrilled to launch our innovative structure with two conviction managers I have known and respected for over 20 years.”
Fixed-income veterans David Roberts and Alex Ralph will run an active global bond fund as the first launch of these in-house managed strategies.
Roberts commented: “I have returned to active investing because market conditions are too compelling to ignore. I have always had conviction to invest when risk and reward are in the client’s favour. After a couple of years when return expectations were negative, we are back in an environment where fixed income is once again a diversifier, a very attractive alternative to equities. The old normal.”
Ralph adds: “Many have been waiting a decade for this type of entry point and the possibility of earning significant, long term positive returns without the need to venture into the dark, equity-like corners of the bond market.”
Addressing the attractions of the firm, Roberts commented: “Nedgroup Investment’s has a long-standing belief in the benefits to investors of boutique models and they share my client-centric approach. Those were the deciding factors for me. It is rare these days to find a business willing to innovate and support a boutique from inception.”
Apiramy Jeyarajah, who joined Nedgroup Investments as Chief Commercial Officer in April 2023, added: “Starting an investment boutique is increasingly difficult. We are excited to offer clients access to compelling teams, complementing the existing boutiques on our platform. Nurturing opportunities with experienced fund managers will help investors benefit from increased choice and a competitive edge.”
About Nedgroup Investments
Nedgroup Investments is a global asset manager with over $20 billion AUM with its international business led from London and global headquarters in Cape Town. Nedgroup Investments is known for its award winning ‘Best of Breed’ partnership model with leading boutique managers in London, Los Angeles, New York and Sydney, offering investors access to the world’s best managers and their funds.
The Nedgroup Investments Boutique Advantage Philosophy
Nedgroup Investments’ fundamental belief is that the best performing investment funds are run by managers that are autonomous, focused and have a concentrated alignment of interests with the unit-holders of their fund.
Fund Range
Nedgroup Investments has two fund ranges – Nedgroup Investments Funds Plc (launched in November 2008) and Nedgroup Investments Multifunds Plc (launched in August 2011).
About David Roberts
David Roberts is a fixed income investor with over 30 years’ experience. He is known for his skin in the game investment style and was previously head of fixed income at Liontrust until early 2022. Previously, he was a fund manager with Aegon Asset Management (formerly Kames Capital) where he was also co-head of fixed income and worked for 14 years. Prior to that, he held roles at Britannia Investment Managers and Lloyds Bank.
About Alex Ralph
Alex Ralph is a highly respected fixed-income fund manager with over two decades of experience in the industry. She is widely recognized for her strong track record of success and is considered one of the leading fixed-income investors of her generation. Alex was most recently a partner at Artemis Investment Management where she helped set up the bond desk launching the Strategic bond fund in 2005. In 2014, she was also appointed lead fund manager on the Artemis high income fund. The desk managed some £3 billion in credit by the end of her tenure at Artemis. Alex holds a BSc in Economics from London School of Economics and is a CFA Charter holder.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230509006145/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Announces US FDA Approval for Label Extensions of ALYFTREK® and TRIKAFTA®, Expanding Availability of These Medicines to ~95% of All People With CF in the United States1.4.2026 13:30:00 CEST | Press release
-With this expansion, any variant that results in production of CFTR protein is now included in the indication for ALYFTREK and TRIKAFTA, reinforcing the impact these medicines have, regardless of the location of the variant in the CFTR protein--Approximately 800 more people with CF in the US are now eligible for a CFTR modulator for the first time- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved expanded use of ALYFTREK® (vanzacaftor/tezacaftor/ivacaftor) for the treatment of people with cystic fibrosis (CF) ages 6 and older with a variant in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is either responsive based on clinical and/or in vitro data or results in production of CFTR protein. Additionally, the U.S. FDA has also expanded the indication statement for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in patients ages 2 and older. This label expansion was supported b
Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer1.4.2026 13:30:00 CEST | Press release
A Landmark Registrational Study Aiming to Redefine Outcomes in MSS mCRC Which Represents Approximately 95% of Metastatic Colorectal Cancer CasesColorectal Cancer Has Become the Leading Cause of Cancer-related Death in Adults Under Age 50 Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that the first patient has been enrolled in the landmark global phase 3 BATTMAN (CO.33) trial (NCT07152821). This study is evaluating Agenus’ immunotherapy combination of botensilimab (BOT) plus balstilimab (BAL) versus best supportive care in patients with refractory, unresectable microsatellite stable (MSS)/mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC), a population long considered resistant to immunotherapy. This study is being conducted as a cooperative group trial led by the Canadian Cancer Trials Group (CCTG) from Canada and run across Canada, France, Australia and New Zealand. More than 100 sites will participate across the academic cooper
Klarna Agrees to $1.7 Billion Transaction Supporting up to $40B+ of Lending1.4.2026 13:19:00 CEST | Press release
Klarna, the global digital bank and flexible payments provider, has entered into a new capital efficiency transaction in the form of a Significant Risk Transfer (SRT), covering $1.7 billion-worth of Euro denominated loans and freeing up capital to support continued growth. Klarna has entered into a three-year agreement with a consortium led by Värde Partners. This is Klarna's sixth SRT transaction and improves how effectively Klarna deploys its capital on a global basis. "Our banking license is one of our biggest competitive advantages," said Niclas Neglén, Klarna's Chief Financial Officer. "This is our largest and most efficient SRT transaction to date. These transactions allow us to maximize every unit of capital to support our continued momentum." The transaction follows Klarna’s recently announced $2 billion facility supporting $17B of US Financing expansion. About Klarna Klarna is a global digital bank and flexible payments provider. With over 118 million global active Klarna user
Americhem Launches nDryve™: PFAS-Free In-Melt Technology Platform for Functional Fibers1.4.2026 13:00:00 CEST | Press release
Americhem, Inc., a global polymer solutions provider, today announced the launch of nDryve™, a PFAS-free, in-melt surface-modifying technology platform designed to deliver durable multi-fluid repellency against alcohol and other low-surface-energy fluids in fiber systems. As global regulations accelerate the phase-out of per- and polyfluoroalkyl substances (PFAS), manufacturers are under increasing pressure to maintain barrier performance without fluorinated chemistries. nDryve™ was developed to address this shift, offering a PFAS-free, in-melt alternative to conventional surface applied treatments. Engineered for Performance Without PFAS Often referred to as “forever chemicals,” PFAS have come under heightened regulatory scrutiny due to their persistence and potential environmental and health impacts. nDryve™ integrates directly into the polymer during melt processing, embedding surface-modifying functionality within the fiber matrix rather than relying on removable finishes. By engin
Biocytogen and Sihuan Pharmaceutical Announce Strategic Partnership in Weight Loss and Beyond1.4.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced a strategic partnership with Sihuan Pharmaceutical Holdings Group Ltd. (Sihuan Pharmaceutical; HKEX: 00460). Under the agreement, both parties will combine Biocytogen’s leading fully human antibody discovery platform with Sihuan Pharmaceutical’s extensive capabilities in drug development, manufacturing, and commercialization. The collaboration will focus on advancing innovative therapies across multiple disease areas, including weight loss, leveraging complementary strengths to drive synergies and establish a long-term strategic partnership. Sihuan Pharmaceutical highly values the strength of Biocytogen’s technology platforms. In this collaboration, Biocytogen will leverage its integrated platforms, including proprietary target-humanized mouse models and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
